Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) is a biotechnology leader pioneering RNA-targeted therapies through its antisense technology platform. This news hub provides investors and industry professionals with comprehensive updates on the company's clinical developments, strategic partnerships, and regulatory milestones.
Access real-time updates on Ionis' innovative research in neurology, cardiology, and rare diseases, including progress on therapies like Qalsody and Wainua. The page aggregates essential information including earnings reports, collaboration announcements with partners such as Biogen and AstraZeneca, and clinical trial outcomes.
Our curated collection serves as your primary source for tracking Ionis' advancements in antisense oligonucleotide development and commercialization strategies. Bookmark this page for streamlined access to verified updates about licensing agreements, patent developments, and therapeutic pipeline expansions.
Ionis Pharmaceuticals (NASDAQ: IONS) announced a live investor day webcast on December 7, 2020, at 11:00 a.m. ET. The event will showcase the company’s commercial strategy, focusing on cardiovascular and neurological franchises, along with recent technological advancements. Key presentations will feature CEO Brett Monia, scientific leaders, and financial executives discussing topics such as market opportunities, pipeline valuation, and future strategies. Interested parties can access the webcast at www.ionispharma.com.
Ionis Pharmaceuticals announced that AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), aimed at lowering cholesterol levels in patients with dyslipidemia. This investigational antisense medicine targets PCSK9, which regulates LDL cholesterol. The randomized trial will enroll about 108 participants and evaluate safety along with efficacy at different doses. Ionis received a $20 million milestone payment from AstraZeneca for the trial initiation, highlighting the collaboration focused on treatments for various diseases.
Ionis Pharmaceuticals (NASDAQ: IONS) announced that AstraZeneca has licensed ION455, an investigational treatment for nonalcoholic steatohepatitis (NASH). This marks the second partnership on NASH between the two companies, following ION839. Ionis received $30 million upfront and can earn up to $300 million in milestones plus royalties. Currently, there are no FDA-approved treatments for NASH, highlighting the significance of this development. Additionally, Ionis is advancing its wholly-owned NASH program, ION224. The company has over 20 medicines in its pipeline.
On November 13, 2020, Ionis Pharmaceuticals (NASDAQ: IONS) presented new data on ION449, an investigational antisense medicine targeting PCSK9 at the AHA Scientific Sessions. The Phase 1 study showed ION449 significantly reduced plasma PCSK9 protein (>90%) and LDL-C levels (~70%) in subjects. Oral administration feasibility was confirmed in animal studies. ION449 aims to provide additional treatment options for cardiovascular disease, which is still a leading cause of death globally, highlighting its potential as a best-in-class therapy.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) will present clinical and non-clinical data for its antisense medicines for cardiovascular disease at the AHA Scientific Sessions 2020, Nov 13-17, 2020. Key presentations include data on ION449, an investigational antisense medicine targeting PCSK9, in collaboration with AstraZeneca. The company will also showcase its treatments for apolipoprotein C-III and lipoprotein(a). Notably, Ionis plans to start a Phase 3 study for AKCEA-APOCIII-LRx by year-end. The event emphasizes Ionis' focus on RNA-targeted therapies to address unmet medical needs in cardiovascular health.
Ionis Pharmaceuticals announced participation in the RNA at the Bench and Bedside II Conference, occurring virtually from Nov. 11-13, 2020. The company will showcase advancements in its antisense technology, particularly in clinical trials for cardiovascular treatments such as pelacarsen and AKCEA-TTR-LRx. Presentations will cover drug delivery methods and the effectiveness of RNA-targeted therapies for heart failure and metabolic diseases. Over 30 industry speakers will participate, highlighting collaboration with universities and key advancements in RNA-targeted therapeutics.
Ionis Pharmaceuticals (Nasdaq: IONS) announced its participation in three upcoming virtual investor conferences. Management will present at:
- Stifel 2020 Healthcare Conference on November 16, 2020;
- Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020;
- Piper Sandler 32nd Annual Healthcare Conference on December 3, 2020.
Live webcasts of each presentation will be available, with replays accessible for a limited time. For updates, visit www.ionispharma.com.
Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS), has received approval from the Scottish Medicines Consortium (SMC) for volanesorsen, enabling access via the NHS in Scotland for treating familial chylomicronaemia syndrome (FCS). This follows NICE's earlier approval in England. Volanesorsen is the only treatment available for FCS in the UK, aimed at reducing triglyceride levels significantly. The SMC's decision is a milestone for FCS patients, allowing access while additional clinical data is collected over three years.
Ionis Pharmaceuticals reported its third-quarter 2020 financial results, showing a net income of $5 million (non-GAAP) but a GAAP net loss of $31 million. The company achieved revenue growth, with commercial revenues of $95 million driven by SPINRAZA royalties of $74 million. The recent acquisition of Akcea strengthens Ionis's pipeline, projecting 10 or more marketing applications by 2025. Cash reserves stand at $2.3 billion post-acquisition, maintaining solid financial health.
